deltatrials
Completed OBSERVATIONAL NCT01687153

A Study of Brain Aging in Vietnam War Veterans (DOD-ADNI)

Effects of Traumatic Brain Injury and Post Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans Using Alzheimer's Disease Neuroimaging Initiative (ADNI)

Sponsor: Alzheimer's Therapeutic Research Institute

Updated 15 times since 2017 Last updated: Nov 24, 2021 Started: Oct 31, 2012 Primary completion: Sep 21, 2021 Completion: Sep 21, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Alzheimer's Disease and Mild Cognitive Impairment, this trial is completed. The trial is conducted by Alzheimer's Therapeutic Research Institute and has accumulated 15 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

The overall long-term goal of this project is to prevent AD, which affects almost 50% of the US population over 85 years of age, and is the most common cause of dementia. Clinical signs and symptoms of AD include cognitive impairments, especially memory and emotional disturbances. In order to accomplish this goal of prevention, a population at risk must be identified. Evidence suggests that both TBI and PTSD increase risk for cognitive decline, AD, and dementia. TBI and PTSD are common problems resulting from military service. Thus far, there have been no prospective studies using imaging and biomarkers, which directly measure changes in the brain and AD pathology to study the effects of TBI and PTSD. This proposed study will provide novel data to test these hypotheses. The results will have major implications for identifying, subjects at increased risk for AD, a possible need for early detection of AD in military Veterans with histories of TBI and PTSD, and a possible need to employ prevention and treatment measures to avoid accelerated development of AD in US military Veterans. This study is a first step toward a larger, more comprehensive study of dementia risk factors in Veterans. The results will lead...

The overall long-term goal of this project is to prevent AD, which affects almost 50% of the US population over 85 years of age, and is the most common cause of dementia. Clinical signs and symptoms of AD include cognitive impairments, especially memory and emotional disturbances. In order to accomplish this goal of prevention, a population at risk must be identified. Evidence suggests that both TBI and PTSD increase risk for cognitive decline, AD, and dementia.

TBI and PTSD are common problems resulting from military service. Thus far, there have been no prospective studies using imaging and biomarkers, which directly measure changes in the brain and AD pathology to study the effects of TBI and PTSD. This proposed study will provide novel data to test these hypotheses. The results will have major implications for identifying, subjects at increased risk for AD, a possible need for early detection of AD in military Veterans with histories of TBI and PTSD, and a possible need to employ prevention and treatment measures to avoid accelerated development of AD in US military Veterans. This study is a first step toward a larger, more comprehensive study of dementia risk factors in Veterans. The results will lead to a design and statistical powering of a prevention trial. Therefore, this project could be the first step toward the prevention of AD in Veterans, and in the general population.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Nov 2019 · 8 months · monthly snapshot~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot

Change History

15 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Dec 2021 — Jul 2024 [monthly]

    Completed

    Status: Unknown StatusCompleted

  5. Nov 2021 — Dec 2021 [monthly]

    Unknown Status

    Status: RecruitingUnknown Status

Show 10 earlier versions
  1. Jan 2021 — Nov 2021 [monthly]

    Recruiting

  2. Nov 2020 — Jan 2021 [monthly]

    Recruiting

  3. Nov 2019 — Nov 2020 [monthly]

    Recruiting

  4. Mar 2019 — Nov 2019 [monthly]

    Recruiting

  5. Jun 2018 — Mar 2019 [monthly]

    Recruiting

  6. May 2018 — Jun 2018 [monthly]

    Recruiting

  7. Apr 2018 — May 2018 [monthly]

    Recruiting

    Phase: NANone

  8. Dec 2017 — Apr 2018 [monthly]

    Recruiting NA

  9. Aug 2017 — Dec 2017 [monthly]

    Recruiting NA

  10. Jan 2017 — Aug 2017 [monthly]

    Recruiting NA

    First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alzheimer's Therapeutic Research Institute
  • Northern California Institute of Research and Education
  • San Francisco Veterans Affairs Medical Center
  • Telemedicine & Advanced Technology Research Center
  • United States Department of Defense
  • University of Southern California
Data source: University of Southern California

For direct contact, visit the study record on ClinicalTrials.gov .